PNAS 2008-07-01

In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.

David Plouffe, Achim Brinker, Case McNamara, Kerstin Henson, Nobutaka Kato, Kelli Kuhen, Advait Nagle, Francisco Adrián, Jason T Matzen, Paul Anderson, Tae-Gyu Nam, Nathanael S Gray, Arnab Chatterjee, Jeff Janes, S Frank Yan, Richard Trager, Jeremy S Caldwell, Peter G Schultz, Yingyao Zhou, Elizabeth A Winzeler

文献索引：Proc. Natl. Acad. Sci. U. S. A. 105 , 9059-64, (2008)

全文：HTML全文

摘要

The growing resistance to current first-line antimalarial drugs represents a major health challenge. To facilitate the discovery of new antimalarials, we have implemented an efficient and robust high-throughput cell-based screen (1,536-well format) based on proliferation of Plasmodium falciparum (Pf) in erythrocytes. From a screen of approximately 1.7 million compounds, we identified a diverse collection of approximately 6,000 small molecules comprised of >530 distinct scaffolds, all of which show potent antimalarial activity (<1.25 microM). Most known antimalarials were identified in this screen, thus validating our approach. In addition, we identified many novel chemical scaffolds, which likely act through both known and novel pathways. We further show that in some cases the mechanism of action of these antimalarials can be determined by in silico compound activity profiling. This method uses large datasets from unrelated cellular and biochemical screens and the guilt-by-association principle to predict which cellular pathway and/or protein target is being inhibited by select compounds. In addition, the screening method has the potential to provide the malaria community with many new starting points for the development of biological probes and drugs with novel antiparasitic activities.